| Size | Price | Stock | Qty |
|---|---|---|---|
| 5mg |
|
||
| 10mg |
|
||
| 50mg |
|
||
| 100mg |
|
||
| Other Sizes |
|
| ln Vitro |
In prelabeled GH3 cells, EWP 815 decreases the basal breakdown rate without influencing the thyrotropin-releasing hormone (TRH; 0.03 mM)-stimulated inositol phospholipid breakdown [1]. The soluble enzyme IC50 is 83 mM, whereas the granzyme is 71 mM. With an average [3H]Ins(1,4)P2 recovery of 2.6[1], EWP 815 (30 μM; 1 hour) suppresses Ins(1,4)P2 phosphatase more than Ins(1,4,5)P3 5-phosphatase. With an IC50 of 6 μM and 8 μM, respectively, EWP 815 (6, 8 μM; 10 min) inhibits the dephosphorylation of [3H]Ins(1,4,5)P3 5-phosphatase in both the soluble and particulate fractions[1]. Without changing Ins (1,4,5)P3 binding, EWP 815 (3-300 μM; 30 min) reduces the amount of inositol phospholipid produced in response to thyrotropin-releasing hormone (TRH) stimulation (100 nM) by 30% at 100 μM and 1.8% at 300 μM, respectively[1].
|
|---|---|
| ln Vivo |
Mice treated intraperitoneally with EWP 815 (50 mg/kg; 30 minutes prior to sacrifice) have their dopamine β-hydroxylase activity inhibited [2].
|
| Animal Protocol |
Animal/Disease Models: Female mice (20 g) [2]
Doses: 50 mg/kg Route of Administration: intraperitoneal (ip) injection; 30 minutes before sacrifice Hydroxylase. The amount of 3H-α-Me-NA was diminished by 12%. |
| References |
| Molecular Formula |
C12H22N4S4
|
|---|---|
| Molecular Weight |
350.58988
|
| Exact Mass |
350.073
|
| CAS # |
20231-01-0
|
| PubChem CID |
30054
|
| Appearance |
White to off-white solid powder
|
| Density |
1.339g/cm3
|
| Boiling Point |
450.5ºC at 760 mmHg
|
| Melting Point |
142ºC
|
| Flash Point |
226.3ºC
|
| Vapour Pressure |
2.62E-08mmHg at 25°C
|
| Index of Refraction |
1.673
|
| LogP |
1.184
|
| Hydrogen Bond Donor Count |
0
|
| Hydrogen Bond Acceptor Count |
6
|
| Rotatable Bond Count |
3
|
| Heavy Atom Count |
20
|
| Complexity |
315
|
| Defined Atom Stereocenter Count |
0
|
| InChi Key |
OOBDBFPYJXJEHC-UHFFFAOYSA-N
|
| InChi Code |
InChI=1S/C12H22N4S4/c1-13-3-7-15(8-4-13)11(17)19-20-12(18)16-9-5-14(2)6-10-16/h3-10H2,1-2H3
|
| Chemical Name |
(4-methylpiperazine-1-carbothioyl)sulfanyl 4-methylpiperazine-1-carbodithioate
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: This product requires protection from light (avoid light exposure) during transportation and storage. |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO : ~50 mg/mL (~142.62 mM)
|
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 1.25 mg/mL (3.57 mM) (saturation unknown) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 12.5 mg/mL clear DMSO stock solution to 900 μL of 20% SBE-β-CD physiological saline solution and mix evenly. Preparation of 20% SBE-β-CD in Saline (4°C，1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. Solubility in Formulation 2: ≥ 1.25 mg/mL (3.57 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 12.5 mg/mL clear DMSO stock solution to 900 μL of corn oil and mix evenly. (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 2.8523 mL | 14.2617 mL | 28.5233 mL | |
| 5 mM | 0.5705 mL | 2.8523 mL | 5.7047 mL | |
| 10 mM | 0.2852 mL | 1.4262 mL | 2.8523 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
